References
- Sasaki K, Mitsui Y, Fukuda M, et al. Intraocular penetration mode of five fluoroquinolone ophthalmic solutions evaluated by the newly proposed parameter of AQCmax. Atarashii Ganka (J Eye) 1995;12:787-90
- Mitsui Y, Oishi M, Sasaki K, et al. Proposal of AQCmax as a pharmacokinetic parameter for ophthalmic solutions. Atarashii Ganka (J Eye) 1995;12:783-6
- Fung-Tomc JC, Minassian B, Kolek B, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44:3351-6
- Stroman DW, Cupp G, Dahlin DC, et al. Human ocular concentrations following topical fluoroquinolones administration relative to susceptibility of ocular pathogens. Invest Ophthalmol Vis Sci 2006;47:ARVO E-Abstract 1881
- Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005;123:39-44
- Zhanel G, Noreddin A. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001;1:459-63
- McCulley JP, Caudle D, Aronowicz JD, et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 2006;113:955-9
- Levine JM, Noecker RJ, Lane LC, et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J Cataract Refract Surg 2004;30:2177-82
- Yagci R, Oflu Y, Dincel A, et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye 2006;10:1038
- Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea 2005;24:955-8
- Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 2005;50:32-45
- Rookaya M, Stewart JM, Prabriputaloong T, et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 2004;138:554-9
- Fukuda M, Takahashi N. Intraocular penetration of gatifloxacin ophthalmic solution in rabbit eyes – calculation of maximum aqueous concentration (AQCmax). Atarashii Ganka (J Eye) 2004;21:1109-12
- Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol 2005;50:1-6
- Langlois MH, Montagut M, Dubost JP, et al. Protonation equilibrium and lipophilicity of moxifloxacin. J Pharm Biomed Anal 2005;37:389-93
- Fukuda M, Sasaki K. In vitro topically applied fluoroquinolone penetration into the anterior chamber. J Jpn Ophthalmol Soc 1995;99:532-6
- Pawar PK, Majumdar DK. Formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS PharmSciTech 2006;7:E1-6
- Rathore MS, Majumdar DK. Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 2006;7:E1-6
- Kawazu K, Midori Y, Shiono H, et al. Characterization of the carrier-mediated transport of levofloxacin, a fluoroquinolone antimicrobial agent, in rabbit cornea. J Pharm Pharmacol 1999 Jul;51:797-801
- Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina 2006;26:191-5
- Lai WW, Chu KO, Chan KP, et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007;144:315-18
- Ong-Tone L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J Cataract Refract Surg 2007;33:59-62